Portfolio Companies

ARDAN Pharma is developing a First-in-Class immunotherapy that aims to address the problem of therapeutic resistance in cancer patients. We own a portfolio of drug candidates that induce pharmacologic inhibition of TMEM176B (TORID), an emerging oncology target, potential biomarker, and resistance factor to current immunotherapies. Our target selection relies on its capacity to modulate anti-tumor responses while simultaneously promoting tumor-cell death.

CaperRX is a preclinical therapeutics company developing a novel proprietary peptide therapy for the safe and universal effective treatment of cancers with the goal to maintain patient quality of life and significantly prolong survival.

Cellergy Pharma is developing a first-in-class immunotherapy for curing severe allergic diseases. By targeting and eliminating the cells that cause allergic disease, we are developing a disease-modifying, and not merely symptom-reducing, life-changing therapeutic product.

Chiima Therapeutics is a pre-clinical early-stage biotech company developing a new small-molecule class of medicines to treat women during their reproductive years. Our therapies are based on world-class science and target the underlying cause of disease rather than simply masking their symptoms. These products may be used either as monotherapy or in combination with current treatments. Chiima has an exclusive option to foundational IP from Stanford.

Flow Medical is enabling data driven pulmonary embolism (PE) interventions. Our next generation lytic catheter combines real time data feedback and advanced engineering to improve the safety and efficacy of interventional PE treatment. Our founders, an interventional cardiologist and interventional radiologist at the University of Chicago, see daily that the current standard of care leads to preventable readmissions and complications. We are working to raise the standard of PE care with a smart catheter that generates the information needed to tie treatment decisions to an individual patient’s needs.

Neuronity is an early-stage biotech company focusing on age-related neurological disorders. Our first indication is Parkinson’s disease. Our technology is based upon an innovative gene therapy that restores healthy immune cell function in aged brains. This First-in-Class immune cell therapy aims to target root causes of Parkinson’s disease to reduce the unmet needs of an increasing number of patients, families, and their caregivers.

Nitro Biosciences is developing a vaccine platform to target difficult-to-immunize antigens in cancer or infectious disease, which cannot be targeted with traditional methods of vaccination. This platform is composed of a two-part solution. First, we reprogram antigens with our nitro modification, which amplifies the body’s immune response toward the antigen. Next, we display these modified antigens on a bacterial delivery vector, enabling delivery to regions of disease, and creating a localized immune response. With promising evidence in animal studies for the use of this technology against several cancer-associated or pathogenic antigens, we are currently translating this technology, developed at the University of Delaware, out of the academic setting where we look to identify a lead indication.

NKILT Therapeutics is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors. PoC has been confirmed! Our initial platform is a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms.

Novaurum is a seed-stage med-tech company spun out of Northeastern University in Boston that is developing novel nanotechnology coatings for medical devices with the goal of achieving better and safer outcomes for patients. AuPEC, the company’s first product, is a coating for orthopedic implants derived from cells and metal nanoparticles to prevent infection, promote tissue regeneration, and protect implants from corrosion and degradation.

At OncoXome, we enable oncologists to safely and effectively treat 30% of all lung cancers, 45% of all colorectal cancers, and 95% of all pancreatic cancers, decreasing chances of relapse by over 90%. We offer a treatment that specifically prevents cancer resistance and induces rapid cancer cell death. Compared with current treatments, OncoXome’s approach is safer, more efficient, less costly, and improves cancer patients’ quality of life.

Ren Bioscience is making sight-saving treatment for retinal disease as simple as taking a pill. Unlike existing therapies that require painful eye injections, our leading compound, Ren-101 is an oral medication that dampens immune and inflammatory responses, protecting the retinal pigment epithelial cells. This revolutionary approach allows for early-stage disease treatment and ultimately saves patients’ sight. At Ren Bioscience, we’re proud to be pioneering a new era in retinal disease treatment.

Score Pharma is developing the next generation of ADCC-enhanced antibody therapeutics. Antibody therapeutics (Ab) like Rituxan, Humira, and Herceptin treat a broad spectrum of diseases. They work by activating the body’s natural immunity. This activation is known as Antibody-Dependent Cellular Cytotoxicity (ADCC). Clinically, ADCC produces a robust immune activation providing therapeutic benefit. However, 80-95% of the patients on currently available Abs have limited clinical responses. ADCC enhancement improves patient responses, and recent FDA approvals of ADCC-enhanced products, including Gazyva, Ocrevus, Fasenra, Poteligo, and Uplizna, validate the use of ADCC-enhanced mAbs. Our CoreX™ technology platform works through the transformation of existing Ab therapeutics to rapidly develop a new ADCC-enhanced product of a clinically established and validated Ab therapeutic.

SingleTimeMicroneedles created a patented, painless, removable, transdermal microneedle platform that can deliver vaccines and therapeutics cheaper, quicker, and more effectively in humans and animals.  STM’s delivery technology is the only platform engineered to deliver single- or multi-dose medications in one application without needles or other equipment. With vaccines, by eliminating pain, refrigerated supply chains, and the need for specially trained health care personnel, STM’s patch will reduce costs, improve patient access, enhance prophylactic outcomes, reduce personnel burdens, and resolve supply chain challenges.

Sonogen Medical is working to commercialize a next-generation ultrasonic bone fracture healing device, with built-in diagnostic fracture healing capability. Sonogen demonstrated in a recent animal trial that our low-intensity pulsed ultrasound signal heals 30% faster than the FDA-approved device currently available for sale in the United States. We have filed multiple worldwide PCT patents protecting our device and related technologies and are currently seeking $2.5M in seed funding for a two-year program culminating in FDA submission.